PMID- 15087780
OWN - NLM
STAT- MEDLINE
DCOM- 20040506
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 77
IP  - 7
DP  - 2004 Apr 15
TI  - Impact of disparity of minor histocompatibility antigens HA-1, CD31, and CD49b in 
      hematopoietic stem cell transplantation of patients with chronic myeloid leukemia 
      with sibling and unrelated donors.
PG  - 1103-6
AB  - Despite human leukocyte antigen (HLA) identity between donor and recipient, 
      several patients develop acute graft-versus-host disease (aGVHD) after 
      hematopoetic stem cell transplantation (HSCT) because of minor histocompatibility 
      antigen (mHag) incompatibilities. The impact of multiple mHag disparities on the 
      clinical outcome after HSCT still remains to be determined. We studied the 
      genomic polymorphisms of HA-1, CD31, and CD49b and correlated mHag distribution 
      with the occurrence of aGVHD after HSCT from HLA-matched sibling and unrelated 
      donors. All 163 patients examined in our single-center study underwent HSCT for 
      chronic myeloid leukemia in the first chronic phase. HA-1 and CD31 disparities 
      are associated with increased aGVHD incidence in a subgroup of patients who test 
      HLA-B44 supertype positive in univariate analysis. However, in a multivariate 
      analysis, only increased patient age was confirmed as an independent aGVHD risk 
      factor. Our findings indicate that the impact of mHag disparity on aGVHD 
      development in HSCT from HLA-matched sibling and unrelated donors seems to be 
      subordinated to classic aGVHD risk factors.
FAU - Heinemann, Falko M
AU  - Heinemann FM
AD  - Institute of Immunology, University Hospital of Essen, Essen, Germany.
FAU - Ferencik, Stanislav
AU  - Ferencik S
FAU - Ottinger, Hellmut D
AU  - Ottinger HD
FAU - Beelen, Dietrich W
AU  - Beelen DW
FAU - Grosse-Wilde, Hans
AU  - Grosse-Wilde H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (HA-1 antigen)
RN  - 0 (Integrin alpha2)
RN  - 0 (Minor Histocompatibility Antigens)
RN  - 0 (Oligopeptides)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
SB  - IM
MH  - Adult
MH  - Graft vs Host Disease/*etiology
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Integrin alpha2/*genetics
MH  - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics/immunology/*therapy
MH  - Minor Histocompatibility Antigens/*genetics
MH  - Oligopeptides/*genetics
MH  - Platelet Endothelial Cell Adhesion Molecule-1/*genetics
MH  - Tissue Donors
EDAT- 2004/04/17 05:00
MHDA- 2004/05/07 05:00
CRDT- 2004/04/17 05:00
PHST- 2004/04/17 05:00 [pubmed]
PHST- 2004/05/07 05:00 [medline]
PHST- 2004/04/17 05:00 [entrez]
AID - 00007890-200404150-00027 [pii]
AID - 10.1097/01.tp.0000120175.25116.cb [doi]
PST - ppublish
SO  - Transplantation. 2004 Apr 15;77(7):1103-6. doi: 
      10.1097/01.tp.0000120175.25116.cb.